Adapting Longstanding Public Health Collaborations between Government of Kenya and CDC Kenya in Response to the COVID-19 Pandemic, 2020-2021.

CDC COVID-19 Centers for Disease Control and Prevention Global Health Security Agenda Kenya PEPFAR SARS SARS-CoV-2 bilateral partnership coronavirus coronavirus disease emerging disease outbreak response global health security respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 15 12 2022
Statut: ppublish

Résumé

Kenya's Ministry of Health (MOH) and the US Centers for Disease Control and Prevention in Kenya (CDC Kenya) have maintained a 40-year partnership during which measures were implemented to prevent, detect, and respond to disease threats. During the COVID-19 pandemic, the MOH and CDC Kenya rapidly responded to mitigate disease impact on Kenya's 52 million residents. We describe activities undertaken jointly by the MOH and CDC Kenya that lessened the effects of COVID-19 during 5 epidemic waves from March through December 2021. Activities included establishing national and county-level emergency operations centers and implementing workforce development and deployment, infection prevention and control training, laboratory diagnostic advancement, enhanced surveillance, and information management. The COVID-19 pandemic provided fresh impetus for the government of Kenya to establish a national public health institute, launched in January 2022, to consolidate its public health activities and counter COVID-19 and future infectious, vaccine-preventable, and emerging zoonotic diseases.

Identifiants

pubmed: 36502403
doi: 10.3201/eid2813.211550
pmc: PMC9745212
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S159-S167

Références

Lancet. 2017 Aug 12;390(10095):632-634
pubmed: 28816126
Am J Trop Med Hyg. 2020 Aug;103(2):564-569
pubmed: 32484156
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JMIR Med Inform. 2018 Apr 18;6(2):e22
pubmed: 29669709
BMC Public Health. 2019 May 10;19(Suppl 3):477
pubmed: 32326916
Emerg Infect Dis. 2017 Dec;23(13):
pubmed: 29155656
PLoS One. 2014 Jun 23;9(6):e98615
pubmed: 24955962
BMC Infect Dis. 2015 Feb 25;15:95
pubmed: 25879805
Lancet. 2015 May 9;385(9980):1884-901
pubmed: 25987157
JAMA. 2021 Jan 5;325(1):17-18
pubmed: 33399836
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
JAMA. 2021 Jan 26;325(4):327-328
pubmed: 33404589
MMWR Morb Mortal Wkly Rep. 2013 Sep 6;62(35):709-13
pubmed: 24005225
PLoS One. 2011 Jan 18;6(1):e16085
pubmed: 21267459
MMWR Morb Mortal Wkly Rep. 2016 Mar 11;65(9):227-30
pubmed: 26963195

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH